Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2024-02-15T05:11:28Z | - |
dc.date.available | 2024-02-15T05:11:28Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 1598-2998 | * |
dc.identifier.issn | 2005-9256 | * |
dc.identifier.other | OAK-34364 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/267683 | - |
dc.description.abstract | Purpose This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL).Materials and Methods Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R -CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy.Results Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent >= grade 3 adverse events (40.0%) and five treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016).Conclusion Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients (ClinicalTrials.gov ID: NCT01054781). | * |
dc.language | English | * |
dc.publisher | KOREAN CANCER ASSOCIATION | * |
dc.subject | Rituximab | * |
dc.subject | Diffuse large B -cell lymphoma | * |
dc.subject | R -CHOP | * |
dc.subject | Response | * |
dc.title | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 55 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 1355 | * |
dc.relation.lastpage | 1362 | * |
dc.relation.journaltitle | CANCER RESEARCH AND TREATMENT | * |
dc.identifier.doi | 10.4143/crt.2023.271|http://dx.doi.org/10.4143/crt.2023.271 | * |
dc.identifier.wosid | WOS:001087738400028 | * |
dc.author.google | Kim, Yu Ri | * |
dc.author.google | Kim, Jin Seok | * |
dc.author.google | Kim, Won Seog | * |
dc.author.google | Eom, Hyeon Seok | * |
dc.author.google | Yang, Deok-Hwan | * |
dc.author.google | Bae, Sung Hwa | * |
dc.author.google | Kim, Hyo Jung | * |
dc.author.google | Lee, Jae Hoon | * |
dc.author.google | Oh, Suk-Joong | * |
dc.author.google | Yoon, Sung -Soo | * |
dc.author.google | Kwak, Jae-Yong | * |
dc.author.google | Choi, Chul Won | * |
dc.author.google | Kim, Min Kyoung | * |
dc.author.google | Oh, Sung Young | * |
dc.author.google | Kang, Hye Jin | * |
dc.author.google | Nam, Seung Hyun | * |
dc.author.google | Shim, Hyeok | * |
dc.author.google | Park, Joon Seong | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Suh, Cheolwon|Korean Soc Hematology Lymphoma | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240502144901 | * |